CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 43 enrolled
Drug / intervention
Cyclosporine +1 moredrug
Likely dose
Cyclosporine 3.0 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00974142
NCT00974142Phase 2Completed

A Randomized, Double-Blinded, Placebo-Controlled Protocol of Oral Cyclosporine in Patients With Advanced Stage Chronic Obstructive Pulmonary Disease

Michael Donahoe·interventional·Posted Sep 10, 2009·Updated Jun 25, 2025

In Brief

A Phase 2 clinical trial evaluating Cyclosporine and Placebo for Chronic Obstructive Pulmonary Disease. Completed, enrolled 43 participants across 1 site.

Detailed Summary

This is a randomized, double-blinded, placebo-controlled trial of oral Cyclosporine A (CsA) in patients with advanced stage chronic obstructive pulmonary disease. The purpose of the study is to evaluate the safety and effectiveness of CsA as a therapy for the adaptive immune response in advanced stage Chronic Obstructive Pulmonary Disease (COPD). Subjects between 45 and 80 years of age with a confirmed diagnosis of advanced stage COPD, not responsive to conventional inhaler therapy, who meet all the study requirements, will be enrolled in this study. A total of 30 subjects of either sex will be enrolled in this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 10, 2009
Enrollment StartSep 1, 2009
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 16.8 years ago

Interventions

Cyclosporinedrug

Fifteen patients will receive cyclosporine at an initial dosing of 3.0 mg/kg/day.

Placebodrug

Fifteen patients will receive will receive placebo.